NUCLEOLIN and retinoblastoma: The aptamers developed against specific proteins (NCL and EpCAM)32,33 whose expression in RB was predominantly validated by flow cytometry using aptamers and by IHC using antibodies, showed only < 60% cells with positive staining on average.